Navigation Links
CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
Date:7/29/2008

estones ahead of schedule including initiation of the Phase II breast cancer trial and accelerated enrollment of patients into the Phase II melanoma trial," commented Dr. Tim Shannon, President and Chief Executive Officer of CuraGen. "Over the remainder of 2008, we look forward to completing enrollment in the melanoma study and subsequently presenting updated results during the fourth quarter of this year."

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com.

Forward-Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to the Company's revenue, expenses, depreciation, amortization, asset impairment charges, losses, income, and future cash and investment positions, including for the second half of 2008 and fiscal year 2008, the timing and expected results of our clinical programs, and the development and marketability of planned drugs, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Sept. 1, 2015  AccuTec Blades, Inc. today announced ... Blades division.  EPC announced in May 2015 its intent ... Verona, Virginia and Obregon, Mexico ... sale process. Rick Gagliano , ... Blades said, "Our new name, AccuTec Blades, reflects the ...
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... DALLAS , Sept. 1, 2015 UT ... and distinguished faculty members joined U.S. Representatives ... in a roundtable discussion on the 21 st ... biomedical research currently being considered by the ... faculty – including National Academy of Sciences members, department ...
Breaking Medicine Technology:AccuTec Blades, Inc. Announces Acquisition of Industrial Blades Division from Edgewell Personal Care Company 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5
... Conn., May 15, 2012 /PRNewswire-iReach/ -- Global ... important Cambridge Healthtech Institute conferences: IMVACS – ... August 13 – 15, Cambridge, MA - The ... under one heading: the Seventh Annual Novel Vaccines, Design ...
... Labs, Inc. (OTCQB/OTCBB: GOVX), a biotechnology company that creates, ... results for the three months ended March 31, 2012 ... delighted with recent developments that have strengthened and advanced ... David Dodd. "Our Phase 1/2 therapeutic vaccine trial continues ...
Cached Medicine Technology:Attendees Save up to $350 on CHI Conferences This Summer by Registering Through Global Information 2GeoVax Labs Reports 2012 First Quarter Financial Results 2GeoVax Labs Reports 2012 First Quarter Financial Results 3GeoVax Labs Reports 2012 First Quarter Financial Results 4GeoVax Labs Reports 2012 First Quarter Financial Results 5GeoVax Labs Reports 2012 First Quarter Financial Results 6
(Date:9/1/2015)... ... September 01, 2015 , ... Philanthropic giving in the U.S. has been ... needs. Money for Good 2015, released today by Camber Collective, goes to the root ... to mobilize up to $22B in new philanthropic giving and shift $25B that’s already ...
(Date:9/1/2015)... ... September 01, 2015 , ... As ... Cross and Blue Shield of Minnesota (Blue Cross) has announced Doctor On Demand ... in San Francisco, Doctor On Demand provides immediate access to Board Certified physicians ...
(Date:9/1/2015)... Plainsboro, NJ (PRWEB) , ... September 01, 2015 ... ... up with Cleveland Clinic, ranked a top-five hospital by U.S. News & World ... care for cancer patients. , Editorial and marketing groups within OncLive, which ...
(Date:9/1/2015)... San Francisco, Calif. (PRWEB) , ... September 01, ... ... services to corporations, law firms and government entities, announced today that it has ... as Senior Discovery Consultant. In this capacity, Sanderson will be responsible for ...
(Date:9/1/2015)... ... September 01, 2015 , ... The FSH Society , ... facioscapulohumeral muscular dystrophy (FSHD), will be the beneficiary of a collection of fundraising events ... to raise awareness of the FSH Society and further FSHD research. , ...
Breaking Medicine News(10 mins):Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3
... A test developed by physician-scientists at Washington University School ... quickly the ability of Alzheimer,s drugs to affect one ... humans, accelerating the development of new treatments. , Scientists ... given to healthy volunteers reduced production of a substance ...
... Academy of Ophthalmology recommends sport-specific eyewear to prevent devastating injuriesOKLAHOMA ... started out as a routine basketball game his senior year ... a young basketball star who played years of hoops without ... eye by a teammate, Stephen ended up with a large ...
... well for skin appearance in 3 trials , , THURSDAY, April ... seems to improve the healing of skin scars, according to ... TGFa3) administered to their skin before wounding and again 24 ... all the way through the skin of the upper inner ...
... Solutions, Inc. ("Allscripts") announced today information related to ... dividend of $5.23 per share distributed in connection ... on October 10, 2008.(Logo: http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO )At ... that in general the special dividend would be ...
... MISSION VIEJO, Calif., April 9 The Ensign Group, ... its Mt. Ogden Health & Rehabilitation Center in Ogden, ... and Medicaid Services, Special Focus Facility program.(Logo: ... small part of what we,re accomplishing as we strive ...
... Pa., April 9 Kensey Nash Corporation (Nasdaq: ... its earnings results for its third quarter ended March ... April 22, 2009. Joe Kaufmann, President and CEO, ... on Wednesday, April 22, 2009 at 9:00 A.M. Eastern ...
Cached Medicine News:Health News:Test quickly assesses whether Alzheimer's drugs are hitting their target 2Health News:Eye Protection is Essential for Oklahoma Athletes 2Health News:Eye Protection is Essential for Oklahoma Athletes 3Health News:Medication May Improve Scar Healing 2Health News:Allscripts Announces Final Tax Treatment of Special Cash Dividend From the Transactions With Misys plc Completed in October 2008 2Health News:The Ensign Group Successfully Graduates Third Nursing Home From CMS Special Focus Program 2Health News:Kensey Nash Corporation Announces Its Third Quarter 2009 Earnings Release Date and Teleconference 2
Straight shafts with 0.12 mm teeth and tying platform. Serrated handle with polished finish....
Angled 45 degree shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Heavy curved shafts with 2 x 2 teeth and crisscross serrated 6 mm tying platform. Serrated handle with polished finish....
Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide serrated handle with polished finish....
Medicine Products: